“A gene-editing Trojan horse that sneaks up on osteosarcoma cells could help the fight against this aggressive childhood bone cancer.” An article by Asia Research News magazine introduced and commented on our previous work which was published in “Biomaterials” (Journal Impact Factors: 8.402). The work entitled “Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma” developed an in vivo osteosarcoma-targeting delivery system for CRISPR/Cas9.
Asia Research News article link: